Curanex Pharmaceuticals (NASDAQ:CURX) Releases Quarterly Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) posted its earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, Zacks reports.

Curanex Pharmaceuticals Trading Up 3.7%

Shares of NASDAQ CURX opened at $0.51 on Tuesday. The firm has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.67. Curanex Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $9.18. The firm has a market capitalization of $14.34 million and a PE ratio of -10.12.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Curanex Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Curanex Pharmaceuticals has a consensus rating of “Sell”.

Institutional Trading of Curanex Pharmaceuticals

An institutional investor recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC purchased a new position in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.